Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial

被引:127
|
作者
Coombes, RC
Bliss, JM
Wils, J
Morvan, F
Espie, M
Amadori, D
Gambrosier, P
Richards, M
Aapro, M
VillarGrimalt, A
McArdle, C
PerezLopez, FR
Vassilopoulos, P
Ferreira, EP
Chilvers, CED
Coombes, G
Woods, EM
Marty, M
机构
[1] GUYS HOSP,ONCOL UNIT,LONDON SE1 9RT,ENGLAND
[2] ROYAL INFIRM,GLASGOW G31 2ER,LANARK,SCOTLAND
[3] CANC RES INST,EPIDEMIOL SECT,SUTTON,SURREY,ENGLAND
[4] ST LAURENTIUS HOSP,ROERMAOND,NETHERLANDS
[5] CTR HOSP RENE DUBOS,PONTOISE,FRANCE
[6] HOP ST LOUIS,PARIS,FRANCE
[7] OSPED GB MORGAGNI & L PIERANTONI,FORLI,ITALY
[8] SAN CARLO HOSP,MILAN,ITALY
[9] HOSP CANTONAL,GENEVA,SWITZERLAND
[10] ARNAU VILANOVA,VALENCIA,SPAIN
[11] HOSP CLIN UNIV,ZARAGOZA,SPAIN
[12] ST SAVAS HOSP,ATHENS,GREECE
[13] INST PORTUGUES ONCOL FRANCISCO GENTIL,OPORTO,PORTUGAL
关键词
D O I
10.1200/JCO.1996.14.1.35
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer. Patients and Methods: The International Collaborative Cancer Group (ICCG) conducted a large randomized trial in which two alternative schedules were used according to participating center: CMF1 versus FECI and CMF2 versus FEC2 Results: Seven hundred fifty-nine patients were entered onto the trial. At a median follow-up time of 4.5 years, no significant benefit for the anthracycline-containing regimen was observed in terms of relapse-free (P = .61) or overall survival (P = .13). FEC1 and CMF1 appear to be of similar efficacy, but there is a suggestion that FEC2 may be superior to CMF2, since patients who received FEC2 had improved overall (P = .02) and relapse-free survival (P = .03) rates. Nausea and vomiting and alopecia were more common in the epirubicin:containing regimen (P = .001). Conclusion: We conclude that the FEC2 regimen, in which epirubicin replaced the methotrexate in CMF, is the preferable adjuvant chemotherapy regimen for premenopausal patients with operable axillary node-positive breast cancer.
引用
收藏
页码:35 / 45
页数:11
相关论文
共 50 条
  • [1] Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
    Levine, MN
    Bramwell, VH
    Pritchard, KI
    Norris, BD
    Shepherd, LE
    Abu-Zahra, H
    Findlay, B
    Warr, D
    Bowman, D
    Myles, J
    Arnold, A
    Vandenberg, T
    MacKenzie, R
    Robert, J
    Ottaway, J
    Burnell, M
    Williams, CK
    Tu, DS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2651 - 2658
  • [2] Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan
    Kimura, Morihiko
    Tominaga, Takeshi
    Takatsuka, Yuichi
    Toi, Masakazu
    Abe, Rikiya
    Koyama, Hiroki
    Takashima, Shigemitsu
    Nomura, Yasuo
    Miura, Shigeto
    Kimijima, Izo
    Tashiro, Hideya
    Ohashi, Yasuo
    [J]. BREAST CANCER, 2010, 17 (03) : 190 - 198
  • [3] Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan
    Morihiko Kimura
    Takeshi Tominaga
    Yuichi Takatsuka
    Masakazu Toi
    Rikiya Abe
    Hiroki Koyama
    Shigemitsu Takashima
    Yasuo Nomura
    Shigeto Miura
    Izo Kimijima
    Hideya Tashiro
    Yasuo Ohashi
    [J]. Breast Cancer, 2010, 17 : 190 - 198
  • [4] Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer
    Radice, D
    Redaelli, A
    [J]. PHARMACOECONOMICS, 2005, 23 (01) : 69 - 75
  • [5] Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer
    Davide Radice
    Alberto Redaelli
    [J]. PharmacoEconomics, 2005, 23 : 69 - 75
  • [6] Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma - Results of a randomized controlled trial
    Bang, SM
    Heo, DS
    Lee, KH
    Byun, JH
    Chang, HM
    Noh, DY
    Choe, KJ
    Bang, YJ
    Kim, SR
    Kim, NK
    [J]. CANCER, 2000, 89 (12) : 2521 - 2526
  • [7] Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
    Levine, MN
    Pritchard, KL
    Bramwell, VHC
    Shepherd, LE
    Tu, DS
    Paul, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5166 - 5170
  • [8] ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN PATIENTS WITH AXILLARY NODE-POSITIVE BREAST-CANCER - AN UPDATE OF THE GUYS MANCHESTER TRIAL
    RICHARDS, MA
    OREILLY, SM
    HOWELL, A
    GEORGE, WD
    FENTIMAN, IS
    CHAUDARY, MA
    CROWTHER, D
    RUBENS, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) : 2032 - 2039
  • [9] Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
    Piccart, MJ
    Di Leo, A
    Beauduin, M
    Vindevoghel, A
    Michel, J
    Focan, C
    Tagnon, A
    Ries, F
    Gobert, P
    Finet, C
    Closon-Dejardin, MT
    Dufrane, JP
    Kerger, J
    Liebens, F
    Beauvois, S
    Bartholomeus, S
    Dolci, S
    Lobelle, JP
    Paesmans, M
    Nogaret, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 3103 - 3110
  • [10] Erratum to: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer
    A. Messori
    P. Becagli
    S. Trippoli
    E. Tendi
    [J]. European Journal of Clinical Pharmacology, 1997, 51 : 427 - 427